Format

Send to:

Choose Destination
See comment in PubMed Commons below
Korean J Urol. 2011 Mar;52(3):157-65. doi: 10.4111/kju.2011.52.3.157. Epub 2011 Mar 18.

Current treatment strategies for castration-resistant prostate cancer.

Author information

  • 1Department of Urology, Ajou University School of Medicine, Suwon, Korea.

Abstract

Prostate cancer is the most common cancer in men in United States and the fifth most common cancer in men in Korea. Although the majority of patients with metastatic prostate cancer initially respond to androgen deprivation therapy, almost all patients will eventually progress to develop castration-resistant prostate cancer (CRPC). Treatment options for CRPC remain limited. Prostate cancer was considered unresponsive to chemotherapy until the mid-1990s, when mitoxantrone combined with prednisone was shown to play a role in the palliative treatment of patients with CRPC. In 2004, two large randomized clinical trials demonstrated for the first time a small but significant survival advantage of docetaxel-based chemotherapy compared with mitoxantrone in patients with metastatic CRPC. Recently, cabazitaxel was shown to improve survival in patients with metastatic CRPC who progressed after docetaxel-based chemotherapy. Sipuleucel-T was also demonstrated to improve overall survival in patients with asymptomatic or minimally symptomatic metastatic CRPC. Along with mitoxantrone and docetaxel, cabazitaxel and sipuleucel-T are now approved for use in metastatic CRPC by the US Food and Drug Administration. There have been multiple early-phase clinical trials of various agents for the treatment of CRPC, and some are in phase III development. This review focuses on the key clinical trials of various treatment options of CRPC currently in use and under investigation.

KEYWORDS:

Drug therapy; Immunotherapy; Molecular targeted therapy; Prostatic neoplasms; Survival

PMID:
21461278
[PubMed]
PMCID:
PMC3065126
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Korean Urological Association Icon for PubMed Central
    Loading ...
    Write to the Help Desk